Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

Source:http://linkedlifedata.com/resource/pubmed/id/16061911

J. Clin. Oncol. 2005 Sep 20 23 27 6719-29

Download in:

View as

Triples

General Info

PMID
16061911